Polymeric nanocarriers for drug delivery to the lung

Journal of Drug Delivery Science and Technology

Volumn 20, Issue 3, 2010, Pages 171-180

  Lebhardt, T ^a   Roesler, S ^a   Beck Broichsitter, M ^a   Kissel, T ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Aerosol; Biodegradable polymers; Inhalator; Lung; Nano carrier; Pulmonary drug delivery; Targeting

Indexed keywords

DNA; MESSENGER RNA; NANOCARRIER; ORGANIC SOLVENT; POLYAMIDE; POLYMER; PROTEIN; SMALL INTERFERING RNA;

ANATOMY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DENATURATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; GENE TARGETING; HUMAN; LUNG; LUNG CANCER; LUNG FUNCTION; NANOENCAPSULATION; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERIZATION; PULMONARY HYPERTENSION; REVIEW; TARGET ORGAN;

EID: 77953828187     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(10)50026-1     Document Type: Review

References (102)

1. Clark A. - Medical aerosol inhalers: past, present, and future. - Aerosol Sci. Technol., 22, 374-391, 1995.
2. Pinto Reis C., Neufeld R., Ribeiro A., Veiga F. - Nanoencapsulation. I. Methods for preparation of drug-loaded polymeric nanoparticles. - Nanomedicine, 2, 8-21, 2006.
3. Vehring R. - Pharmaceutical particle engineering via spray drying. - Pharm. Res., 25, 999-1022, 2008.
4. Avgoustakis K. - Pegylated poly(lactide) and poly(lactide-coglycolide) nanoparticles: preparation, properties and possible applications in drug delivery. - Curr. Drug Delivery, 1, 321-333, 2004.
5. Wischke C., Schwendeman S. - Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. - Int. J. Pharm., 364, 298-327, 2008.
6. Barichello J.M., Morishita M., Takayama K., Nagai T. - Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. - Drug Dev. Ind. Pharm., 25, 471-476, 1999.
7. Weibel E. - Morphology of the Human Lung. - Springer-Verlag, Berlin, 1963.
8. Stone K., Mercer R., Gehr P., Stockstill B., Crapo J. - Allometric relationships of cell numbers and size in the mammalian lung. - Am. J. Respir. Cell Mol. Biol., 6, 235, 1992.
9. Heyder J., Gebhart J., Rudolf G., Schiller C., Stahlofen W. - Deposition of particles in the human respiratory tract in the size range 0, 005-15 m. - J. Aerosol. Sci., 17, 811-825, 1986. (Pubitemid 17492310)
10. Bailey M.R. - The new ICRP model for the respiratory tract. - Radiat. Prot. Dosim., 53, 107-114, 1994.
11. Evans C., Koo J. - Airway mucus: the good, the bad, the sticky. - Pharmacol. Ther., 121, 332-348, 2009.
12. Chow A., Tong H., Chattopadhyay P., Shekunov B. - Particle engineering for pulmonary drug delivery. - Pharm. Res., 24, 411-437, 2007.
13. Patton J., Byron R - Inhaling medicines: delivering drugs to the body through the lungs. - Nat. Rev. Drug Discov., 6, 67-74, 2007.
14. Gessler T., Seeger W., Schmehl T. - Inhaled prostanoids in the therapy of pulmonary hypertension. - J. Aerosol Med. Pulm. Drug Deliv., 21, 1-12, 2008.
15. Dailey L., Wittmar M., Kissel T. - The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. - J. Control. Rel., 101, 137-149, 2005.
16. Rytting E., Nguyen J., Wang X., Kissel T. - Biodegradable polymeric nanocarriers for pulmonary drug delivery. - Expert Opin. Drug Deliv., 5, 629-639, 2008.
17. James J., Crean B., Davies M., Toon R., Jinks P., Roberts C. - The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. - Int. J. Pharm., 361, 209-221, 2008.
18. Engstrom J., Tam J., Miller M., Williams R., Johnston K. -Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. - Pharm. Res., 26, 101-117, 2009.
19. Nyambura B.K., Kellaway I.W., Taylor K.M.G. - Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers. - Int. J. Pharm., 375, 114-122, 2009.
20. Nyambura B.K., Kellaway I.W., Taylor K.M.G. - The processing of nanoparticles containing protein for suspension in hydrofluoroalkane propellents. - Int. J. Pharm., 372, 140-146, 2009.
21. Freitas C., Müller R. - Spray-drying of Solid Lipid Nanoparticles (SLN™) - Eur. J. Pharm. Biopharm., 46, 145-151, 1998. (Pubitemid 28414472)
22. Sham J.O.H., Zhang Y., Finlay W.H., Roa W.H., Lobenberg R. - Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. - Int. J. Pharm., 269, 457-467, 2004.
23. Tewa-Tagne P., Briançon S., Fessi H. - Preparation of redispersible dry nanocapsules by means of spray-drying: development and characterisation. - Eur. J. Pharm. Sci., 30, 124-135, 2007.
24. Yamamoto H., Hoshina W., Kurashima H., Takeuchi H., Kawashima Y., Yokoyama T., Tsujimoto H. - Engineering of poly (DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. - Adv. Powder Technol., 18, 215-228, 2007.
25. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T. - Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. - J. Control. Rel., 86, 131-144, 2003.
26. Packhaeuser C., Lahnstein K., Sitterberg J., Schmehl T., Gessler T., Bakowsky U., Seeger W., Kissel T. - Stabilization of aerosolizable nano-carriers by freeze-drying. - Pharm. Res., 26, 129-138, 2009.
27. McKone E., Aitken M. - Cystic fibrosis: disease mechanisms and therapeutic targets. - Drug Discov. Today Dis. Mech., 1, 137-143, 2004.
28. Boucher R. - Cystic fibrosis: a disease of vulnerability to airway surface dehydration. - Trends Mol. Med, 13, 231-240, 2007.
29. Suk J., Lai S., Wang Y., Ensign L., Zeitlin P., Boyle M., Hanes J. - The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. - Biomaterials, 30, 2591-2597, 2009.
30. Tang B., Dawson M., Lai S., Wang Y., Suk J., Yang M., Zeitlin P., Boyle M., Fu J., Hanes J. - Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. - Proc. Nat. Acad. Sci., 106, 19268-19273, 2009.
31. Bateman E., Hurd S., Barnes P., Bousquet J., Drazen J., FitzGerald M., Gibson P., Ohta K., O'Byrne P., Pedersen S. - Global strategy for asthma management and prevention: GINA executive summary. - Eur. Resp. J., 31, 143, 2008.
32. Zock J.-P., Plana E., Jarvis D., Anto J.M., Kromhout H., Kennedy S.M., Kunzli N., Villani S., Olivieri M., Toren K., Radon K., Sunyer J., Dahlman-Hoglund A., Norback D., Kogevinas M. - The use of household cleaning sprays and adult asthma: an international longitudinal study. - Am. J. Respir. Crit. Care Med., 176, 735-741, 2007.
33. Celli B., MacNee W., Agusti A., Anzueto A., Berg B., Buist A., Calverley P., Chavannes N., Dillard T., Fahy B. - Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. - Eur. Resp. J., 23, 932-946, 2004.
34. Molfino N., Jeffery P. - Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. - Pulm. Pharmacol. Ther., 20, 462-472, 2007.
35. Albert P., Calverley P. - Drugs (including oxygen) in severe COPD. - Eur. Resp. J., 31, 1114, 2008.
36. Rytting E., Bur M., Cartier R., Bouyssou T., Wang X., Krüger M., Lehr C.-M., Kissel T. - In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles - J. Control. Rel., 141, 101-107, 2009.
37. Beck-Broichsitter M., Gauss J., Gessler T., Seeger W., Kissel T., Schmehl T. - Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. - J. Aerosol Med. Pulm. Drug Deliv., 23, 47-57, 2010.
38. World Health Organization. - Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. - Publication No. WHO/HTM/TB/2009.411, Geneva, 2009.
39. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., Prasad B. - Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. - J. Antimicrob. Chemother., 52, 981-986, 2003.
40. Sun S., Schiller J.H., Spinola M., Minna J.D. - New molecularly targeted therapies for lung cancer. - J. Clin. Invest., 117, 2740-2750, 2007.
41. Dames P., Gleich B., Flemmer A., Hajek K., Seidl N., Wiekhorst F., Eberbeck D., Bittmann I., Bergemann C., Weyh T., Trahms L., Rosenecker J., Rudolph C. - Targeted delivery of magnetic aerosol droplets to the lung. - Nat. Nanotechnol., 2, 495-499, 2007.
42. Chin K.M., Rubin L.J. - Pulmonary arterial hypertension. - J. Am. Coll. Cardiol., 51, 1527-1538, 2008.
43. Smola M., Vandamme T., Sokolowski A. - Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. - Int. J. Nanomed., 3, 1-19, 2008.
44. Petruzzelli S., Camus A.-M., Carrozzi L., Ghelarducci L., Rindi M., Menconi G., Angeletti C.A., Ahotupa M., Hietanen E., Aitio A., Saracci R., Bartsch H., Giuntini C. - Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. - Cancer Res., 48, 4695-4700, 1988.
45. Sakagami M. - In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. - Adv. Drug Deliv. Rev., 58, 1030-1060, 2006.
46. Seeger W., Walmrath D., Grimminger F., Rosseau S., Schütte H., Krämer H., Ermert L., Kiss L. - Adult respiratory distress syndrome: model systems using isolated perfused rabbit lungs. - Methods Enzymol., 233, 549-584, 1994.
47. Beck-Broichsitter M., Gauss J., Packhaeuser C., Lahnstein K., Schmehl T., Seeger W., Kissel T., Gessler T. - Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. - Int. J. Pharm., 367, 169-178, 2009.
48. Liu X., Wang J.Y., Khlentzos A.M., Fontaine F., Nikolovski J., Goh L.-A., Roberts M.S. - Influence of perfusate composition on drug disposition in the in situ perfused rat lung. - Int. J. Pharm., 382, 192-197, 2009.
49. Kumari A., Yadav S.K., Yadav S.C. - Biodegradable polymeric nanoparticles based drug delivery systems. - Colloid Surf. B-Biointerfaces, 75, 1-18, 2009.
50. Anderson J., Shive M. - Biodegradation and biocompatibility of PLA and PLGA microspheres. - Adv. Drug Deliv. Rev., 28, 5-24, 1997.
51. Corrigan O., Li X. - Quantifying drug release from PLGA nanoparticulates. - Eur. J. Pharm. Sci., 37, 477-485, 2009.
52. Panyam J., Dali M.M., Sahoo S.K., Ma W., Chakravarthi S.S., Amidon G.L., Levy R.J., Labhasetwar V. - Polymer degradation and in vitro release of a model protein from poly(lactide-co-glycolide) nano- and microparticles - J. Control. Rel., 92, 173-187, 2003.
53. Unger F., Wittmar M., Morell F., Kissel T. - Branched polyesters based on poly[vinyl-3-(dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly(d,l-lactide-co-glycolide): effects of polymer structure on in vitro degradation behaviour. - Biomaterials, 29, 2007-2014, 2008.
54. Scherer D., Robinson J.R., Kreuter J. - Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles. - Int. J. Pharm., 101, 165-168, 1994.
55. Kean T., Thanou M. - Biodegradation, biodistribution and toxicity of chitosan. - Adv. Drug Deliv. Rev., 62, 3-11, 2010.
56. Tabata Y., Murakami Y., Ikada Y. - Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. - J. Control. Release, 50, 123-133, 1998.
57. Jung T., Breitenbach A., Kissel T. - Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-coglycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. - J. Control. Rel., 67, 157-169, 2000.
58. Chittasupho C., Xie S., Baoum A., Yakovleva T., Siahaan T., Berkland C. - ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. - Eur. J. Pharm. Sci., 37, 141-150, 2009.
59. Tseng C., Su W., Yen K., Yang K., Lin F. - The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. - Biomaterials, 30, 3476-3485, 2009.
60. Tomoda K., Ohkoshi T., Hirota K., Sonavane G., Nakajima T., Terada H., Komuro M., Kitazato K., Makino K. - Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. - Colloid Surf. B-Biointerfaces, 71, 177-182, 2009.
61. Sung J., Padilla D., Garcia-Contreras L., VerBerkmoes J., Durbin D., Peloquin C., Elbert K., Hickey A., Edwards D. - Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. - Pharm. Res., 26, 1847-1855, 2009.
62. Ohashi K., Kabasawa T., Ozeki T., Okada H. - One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. - J. Control. Rel., 135, 19-24, 2009.
63. Pietzonka P., Rothen-Rutishauser B., Langguth P., Wunderli-Allenspach H., Walter E., Merkle H. - Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to Caco-2 monolayers mimics particle uptake. - Pharm. Res., 19, 595-601, 2002.
64. Ely L., Roa W., Finlay W., Löbenberg R. - Effervescent dry powder for respiratory drug delivery. - Eur. J. Pharm. Biopharm., 65, 346-353, 2007.
65. Azarmi S., Löbenberg R., Roa W., Tai S., Finlay W. - Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. - Drug Dev. Ind. Pharm., 34, 943-947, 2008.
66. Beyerle A., Höbel S., Czubayko F., Schulz H., Kissel T., Aigner A., Stoeger T. - In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. - Toxicol. Vitro, 23, 500-508, 2009.
67. Adi H., Young P., Chan H., Stewart P., Agus H., Traini D. - Cospray dried antibiotics for dry powder lung delivery. - J. Pharm. Sci., 97, 3356-3366, 2008.
68. Salama R., Hoe S., Chan H., Traini D., Young P. - Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation. 1. Influence of polymer concentration on physical and in vitro characteristics - Eur. J. Pharm. Biopharm., 69, 486-495, 2008.
69. Salama R.O., Traini D., Chan H.-K., Young P.M. - Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation. 2. Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. - Eur. J. Pharm. Biopharm., 70, 145-152, 2008.
70. Gul M., Jones S., Dailey L., Nacer H., Ma Y., Sadouki F., Hider R., Araman A., Forbes B. - A poly (vinyl alcohol) nanoparticle platform for kinetic studies of inhaled particles. - Inhal. Toxicol., 21, 631-640, 2009.
71. Madlova M., Jones S., Zwerschke I., Ma Y., Hider R., Forbes B. - Poly (vinyl alcohol) nanoparticle stability in biological media and uptake in respiratory epithelial cell layers in vitro. - Eur. J. Pharm. Biopharm., 72, 438-443, 2009.
72. Kawashima Y., Yamamoto H., Takeuchi H., Fujioka S., Hino T. - Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. - J. Control. Release, 62, 279-287, 1999.
73. Grenha A., Seijo B., Remuñán-López C. - Microencapsulated chitosan nanoparticles for lung protein delivery. - Eur. J. Pharm. Sci., 25, 427-437, 2005.
74. Amidi M., Pellikaan H., de Boer A., Crommelin D., Hennink W., Jiskoot W. - Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. - Eur. J. Pharm. Biopharm., 68, 191-200, 2008.
75. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., Kawashima Y. - Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. - J. Control. Release, 102, 373-381, 2005.
76. Zhang Q., Shen Z., Nagai T. - Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. - Int. J. Pharm., 218, 75-80, 2001.
77. Lungwitz U., Breunig M., Blunk T., Göpferich A. - Polyethylenimine-based non-viral gene delivery systems. - Eur. J. Pharm. Biopharm., 60, 247-266, 2005.
78. Thomas M., Lu J., Zhang C., Chen J., Klibanov A. - Identification of novel superior polycationic vectors for gene delivery by high-throughput synthesis and screening of a combinatorial library. - Pharm. Res., 24, 1564-1571, 2007.
79. Jere D., Xu C., Arote R., Yun C., Cho M., Cho C. - Poly (β-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. - Biomaterials, 29, 2535-2547, 2008.
80. Arote R., Kim T., Kim Y., Hwang S., Jiang H., Song H., Nah J., Cho M., Cho C. - A biodegradable poly (ester amine) based on polycaprolactone and polyethylenimine as a gene carrier. - Biomaterials, 28, 735-744, 2007.
81. Germershaus O., Mao S., Sitterberg J., Bakowsky U., Kissel T. - Gene delivery using chitosan, trimethyl chitosan or polyethylenglycol-graft-trimethyl chitosan block copolymers: establishment of structure-activity relationships in vitro. - J. Control. Rel., 125, 145-154, 2008.
82. MacLaughlin F., Mumper R., Wang J., Tagliaferri J., Gill I., Hinchcliffe M., Rolland A. - Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. - J. Control. Rel., 56, 259-272, 1998.
83. Köping-Höggård M., Tubulekas I., Guan H., Edwards K., Nilsson M., Vårum K., Artursson P. - Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. - Gene Ther., 8, 1108-1121, 2001.
84. Köping-Höggård M., Vårum K., Issa M., Danielsen S., Christensen B., Stokke B., Artursson P. - Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. - Gene Ther., 11, 1441-1452, 2004.
85. Howard K., Rahbek U., Liu X., Damgaard C., Glud S., Andersen M., Hovgaard M., Schmitz A., Nyengaard J., Besenbacher F. - RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. - Mol. Ther., 14, 476-484, 2006.
86. Liu X., Howard K., Dong M., Andersen M., Rahbek U., Johnsen M., Hansen O., Besenbacher F., Kjems J. - The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. - Biomaterials, 28, 1280-1288, 2007. (Pubitemid 44816373)
87. Jere D., Jiang H., Kim Y., Arote R., Choi Y., Yun C., Cho M., Cho C. - Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. - Int. J. Pharm., 378, 194-200, 2009.
88. Zou W., Liu C., Chen Z., Zhang N. - Studies on bioadhesive PLGA nanoparticles: a promising gene delivery system for efficient gene therapy to lung cancer - Int. J. Pharm., 370, 187-195, 2009.
89. Tahara K., Yamamoto H., Hirashima N., Kawashima Y. - Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. - Eur. J. Pharm. Biopharm., 74, 421-426, 2010.
90. Nafee N., Taetz S., Schneider M., Schaefer U., Lehr C. - Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. - Nanomedicine, 3, 173-183, 2007.
91. Baoum A., Dhillon N., Buch S., Berkland C. - Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. - J. Pharm. Sci., 99, 2413-2422, 2010.
92. Nguyen J., Steele T., Merkel O., Reul R., Kissel T. - Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. - J. Control. Release, 132, 243-251, 2008.
93. Nguyen J., Reul R., Betz T., Dayyoub E., Schmehl T., Gessler T., Bakowsky U., Seeger W., Kissel T. - Nanocomposites of lung surfactant and biodegradable cationic nanoparticles improve transfection efficiency to lung cells. - J. Control. Rel., 140, 47-54, 2009.
94. Reul R., Nguyen J., Kissel T. - Amine-modified hyperbranched polyesters as non-toxic, biodegradable gene delivery systems. - Biomaterials, 30, 5815-5824, 2009.
95. Kleinstreuer C., Shi H., Zhang Z. - Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology. - J. Aerosol Med. Pulm. Drug Deliv., 20, 294-309, 2007.
96. Pringle I., Hyde S., Gill D. - Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects. - Expert Opin. Biol. Ther., 9, 991-1003, 2009.
97. Durcan N., Murphy C., Cryan S. - Inhalable siRNA: potential as a therapeutic agent in the lungs. - Mol. Pharm., 5, 559-566, 2008.
98. Sci S., Wegmann M., Dicke T., Henke W., Yildirim A., Renz H., Garn H. - Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. - Journal of Allergy and Clinical Immunology, 121, 910-916, 2008.
99. Ito T., Ozawa K., Shimada K. - Current drug targets and future therapy of pulmonary arterial hypertension. - Curr. Med. Chem., 14, 719-733, 2007.
100. De Koker S., Naessens T., De Geest B.G., Bogaert P., Demeester J., De Smedt S., Grooten J. - Biodegradable polyelectrolyte microcapsules: antigen delivery tools with Th17 skewing activity after pulmonary delivery. - J. Immunol., 184, 203-211.
101. Bailey C., Barnett A. - Why is Exubera being withdrawn? - Br. Med. J., 335, 1156, 2007.
102. Lurje G., Lenz H. - EGFR signaling and drug discovery. - Oncology, 77, 400-410, 2009.